Novo Nordisk A/S banner

Novo Nordisk A/S
F:NOVC

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
F:NOVC
Watchlist
Price: 90.7 EUR -1.52%
Market Cap: €203.5B

Relative Value

The Relative Value of one NOVC stock under the Base Case scenario is hidden EUR. Compared to the current market price of 90.7 EUR, Novo Nordisk A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NOVC Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
F:NOVC
1.1T EUR 3.5 10.4 7.7 9.1
US
Eli Lilly and Co
NYSE:LLY
989.2B USD 15.2 48 32.4 34.4
US
Johnson & Johnson
NYSE:JNJ
593.2B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
294.8B CHF 4.8 31.4 13.2 15.4
UK
AstraZeneca PLC
LSE:AZN
237.1B GBP 5.4 31.2 17.3 24.3
CH
Novartis AG
SIX:NOVN
248.7B CHF 5.7 22.9 14.1 18.1
US
Merck & Co Inc
NYSE:MRK
310.9B USD 4.7 16.9 10.5 12.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
154.8B USD 2.5 19.8 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
124.9B USD 2.6 17.7 7.4 9.1
UK
GSK plc
XETRA:GS71
102.8B EUR 2.7 15.7 7.9 11.3
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
F:NOVC
Average P/E: 23.6
10.4
7%
1.5
US
Eli Lilly and Co
NYSE:LLY
48
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.4
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.2
26%
1.2
CH
Novartis AG
SIX:NOVN
22.9
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.9
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
19.8
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.7
17%
1
UK
GSK plc
XETRA:GS71
15.7
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBITDA: 43.5
7.7
7%
1.1
US
Eli Lilly and Co
NYSE:LLY
32.4
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.3
11%
1.6
CH
Novartis AG
SIX:NOVN
14.1
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.5
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-12%
N/A
UK
GSK plc
XETRA:GS71
7.9
2%
4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBIT: 93.4
9.1
8%
1.1
US
Eli Lilly and Co
NYSE:LLY
34.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.4
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
24.3
24%
1
CH
Novartis AG
SIX:NOVN
18.1
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-6%
N/A
UK
GSK plc
XETRA:GS71
11.3
12%
0.9
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett